Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Enterprise Value (2021 - 2025)

Historic Enterprise Value for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to -$731.1 million.

  • Krystal Biotech's Enterprise Value fell 2426.3% to -$731.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$731.1 million, marking a year-over-year decrease of 2426.3%. This contributed to the annual value of -$597.5 million for FY2024, which is 1227.77% down from last year.
  • Per Krystal Biotech's latest filing, its Enterprise Value stood at -$731.1 million for Q3 2025, which was down 2426.3% from -$682.0 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Enterprise Value peaked at -$343.1 million during Q3 2021, and registered a low of -$731.1 million during Q3 2025.
  • Over the past 5 years, Krystal Biotech's median Enterprise Value value was -$477.5 million (recorded in 2023), while the average stood at -$495.9 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first soared by 1938.31% in 2023, then plummeted by 5361.84% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Enterprise Value stood at -$438.1 million in 2021, then increased by 13.45% to -$379.2 million in 2022, then plummeted by 40.35% to -$532.2 million in 2023, then dropped by 12.28% to -$597.5 million in 2024, then dropped by 22.35% to -$731.1 million in 2025.
  • Its Enterprise Value was -$731.1 million in Q3 2025, compared to -$682.0 million in Q2 2025 and -$616.8 million in Q1 2025.